The changing landscape of molecular radiotherapy

Author(s): Dr Glenn Flux

Hospital: Royal Marsden Hospital NHS Foundation Trust

Reference: RAD Magazine, 44, 519, 15-16


Radionuclide therapy is probably the only field of medicine that allows direct imaging of a drug as it is used to treat cancer. Radioiodine was first used over 70 years ago for the treatment of benign thyroid disease and thyroid cancer. Levels of activity to administer were determined empirically, influenced largely by limitations in supply from newly commissioned cyclotrons. After many decades of little growth, a dramatic increase in radiotherapeutics now heralds what is promising to be a step change in this area of cancer management. Significant changes are being seen in terms of the products available, the costs associated with these products, treatment regimens and regulations.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more